3 results
Primary: To characterize the safety and tolerability of PDR001 in combination with LCL161, everolimus, HDM201, QBM076 or panobinostat and to identify recommended doses and schedules for future studies.Secondary: To characterize changes in the immune…
Double-blind Phase:Primary Objective:To evaluate the efficacy of birtamimab plus standard of care compared to placebo plus standard of care when administered intravenously in Mayo Stage IV subjects with AL amyloidosis by assessing time to all-cause…
The three key outcome measurements and challenges of this proof of concept study are to achieve a decrease in ongoing HO bone formation, decrease in numbers of disease *flare-up* episodes and to prevent the continuation of FOP induced contractures.…